Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Stock Performance

NASDAQ AEMD opened at $0.35 on Friday. Aethlon Medical has a one year low of $0.24 and a one year high of $1.79. The company has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.22 and a beta of 1.71. The company’s 50-day simple moving average is $0.53 and its two-hundred day simple moving average is $0.50.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.09. Equities analysts expect that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AEMD. Boothbay Fund Management LLC purchased a new position in Aethlon Medical in the fourth quarter worth $186,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical in the 4th quarter worth $31,000. Renaissance Technologies LLC purchased a new position in Aethlon Medical during the 4th quarter worth $25,000. Virtu Financial LLC acquired a new position in Aethlon Medical during the 4th quarter valued at about $81,000. Finally, Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at about $26,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.